Search Clinical Trials
Sponsor Condition of Interest |
---|
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
Vaccine Company, Inc.
SARS-CoV
SARS-CoV-2
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose
levels of VXCO-100 in healthy adults. expand
The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in healthy adults. Type: Interventional Start Date: May 2023 |
Q-POC SARS-CoV-2 Assay COVID-19 Clinical Evaluation
QuantuMDx Group Ltd
COVID-19
Q-POC SARS-CoV-2 moderate complexity PCR test performance evaluation expand
Q-POC SARS-CoV-2 moderate complexity PCR test performance evaluation Type: Interventional Start Date: Nov 2022 |
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
AIM ImmunoTech Inc.
Post COVID-19 Condition
Long COVID
The purpose of this study is to assess the efficacy and safety of Ampligen® administered
twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID
Condition of fatigue. expand
The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue. Type: Interventional Start Date: Jun 2023 |
Transplacental Transmission of RSV (TTRSV)
Tulane University
SARS CoV 2 Infection
Respiratory Syncytial Virus (RSV)
Bronchiolitis
Asthma
Aim 1: To study transplacental transmission of Respiratory Syncytial Virus (RSV) and how
this is moderated by other maternal infections during pregnancy
Aim 2: To test maternal blood for presence of RSV-specific immunoglobulins and how this
is moderated by other maternal infections during pregnancy
Aim... expand
Aim 1: To study transplacental transmission of Respiratory Syncytial Virus (RSV) and how this is moderated by other maternal infections during pregnancy Aim 2: To test maternal blood for presence of RSV-specific immunoglobulins and how this is moderated by other maternal infections during pregnancy Aim 3: To test cord blood (fetal blood) for presence of RSV-specific immunoglobulins and other common viral pathogens Aim 4: To perform further tests (Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Droplet Digital Polymerase Chain Reaction (ddPCR) and immunoprobing) to confirm the presence of RSV and other common viral pathogens Aim 5: To follow these newborn infants up to 4 years of age to look for redisposition to respiratory diseases and growth parameters Type: Observational Start Date: May 2020 |
Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children
Carelon Research
Multisystem Inflammatory Syndrome in Children (MIS-C)
Multi-system Inflammatory Syndrome in Children (MIS-C) is a new condition related to
COVID-19, the study investigators are still learning about its causes, effects, and
long-term impact. "Long-Term Outcomes after the Multisystem Inflammatory Syndrome In
Children", the Coronavirus MUSIC Study, is a... expand
Multi-system Inflammatory Syndrome in Children (MIS-C) is a new condition related to COVID-19, the study investigators are still learning about its causes, effects, and long-term impact. "Long-Term Outcomes after the Multisystem Inflammatory Syndrome In Children", the Coronavirus MUSIC Study, is a research study funded by NIH and the National Heart, Lung, and Blood Institute. The study investigators hope to enroll at least 900 young people with MIS-C at children's medical centers in the U.S. and Canada. This research study will help us learn more about MIS-C and its effects on the long-term health of children. Type: Observational Start Date: Sep 2020 |
Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults
Techfields Inc
COVID-19 Pneumonia
Techfields Inc. is developing a new investigational prodrug as a topical spray, indicated
for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19. This is a
Phase 2, Multicenter, Randomized, Double-blind (Within Dose), Placebo-controlled,
Parallel-group, and Dose-range-finding... expand
Techfields Inc. is developing a new investigational prodrug as a topical spray, indicated for relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19. This is a Phase 2, Multicenter, Randomized, Double-blind (Within Dose), Placebo-controlled, Parallel-group, and Dose-range-finding Study to Evaluate the Efficacy and Safety of Active drug Versus Placebo in Treatments for COVID-19 in Hospitalized Adults, relieving of the signs and symptoms of acute respiratory distress syndrome (ARDS) and pneumonia caused by coronavirus disease 2019 (COVID-19). Type: Interventional Start Date: May 2022 |
Novel Experimental COVID-19 Therapies Affecting Host Response
Sean Collins
COVID-19
SARS-CoV-2 Infection
Coronavirus Infection
The overarching goal of the Master Protocol is to find effective strategies for inpatient
management of patients with COVID-19. Therapeutic goals for patients hospitalized for
COVID-19 include hastening recovery and preventing progression to critical illness,
multiorgan failure, or death. Our objective... expand
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19. Type: Interventional Start Date: Jul 2021 |
Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test...
Medical College of Wisconsin
Covid19
This clinical study is designed to test the efficacy of the Novir 2019-nCoV
Immunoglobulin M/Immunoglobulin G Antibody Test in a point-of-care setting to support the
increasing need for rapid screening in the detection of antibodies. The study is
performed on individuals who have no history of COVID-19... expand
This clinical study is designed to test the efficacy of the Novir 2019-nCoV Immunoglobulin M/Immunoglobulin G Antibody Test in a point-of-care setting to support the increasing need for rapid screening in the detection of antibodies. The study is performed on individuals who have no history of COVID-19 and no history of COVID immunization as well as individuals with history of COVID-19 that was diagnosed greater than 15 days. This is performed both through 3mL venous whole blood which is ran through an assay as well a point-of-care rapid test which is resulted in 10 minutes. Aiding in the rapid detection of COVID-19 antibodies. Type: Observational Start Date: Apr 2021 |
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
Aptabio Therapeutics, Inc.
COVID-19
This phase 2 study is to assess the safety and tolerability of APX-115 active doses
compared to placebo following multiple oral dosing in hospitalized patients with
confirmed, mild to moderate, symptomatic COVID-19. It is anticipated that approximately
80 patients will be randomized into the study... expand
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19. It is anticipated that approximately 80 patients will be randomized into the study in a 1:1 ratio to 100 mg APX-115 or placebo arm. Type: Interventional Start Date: Oct 2021 |
Leveraging CHWs to Improve COVID-19 Testing and Mitigation Among CJIs Accessing a Corrections-focused...
Montefiore Medical Center
Covid19
Given the likelihood of COVID-19 remaining an endemic disease among high-risk
populations, establishing effective mitigation interventions will be critical to stemming
community transmission. Criminal justice-involved individuals are extremely important to
reducing community-based SARS-CoV-2 transmission... expand
Given the likelihood of COVID-19 remaining an endemic disease among high-risk populations, establishing effective mitigation interventions will be critical to stemming community transmission. Criminal justice-involved individuals are extremely important to reducing community-based SARS-CoV-2 transmission due to their increased risk of contracting SARS-CoV-2 while incarcerated and their likelihood of living in congregate settings after incarceration. The investigators will evaluate an onsite Point-of-Care SARS-CoV-2 testing and education strategy in a corrections-focused community-based organization and its impact on improving testing uptake, mitigation behaviors(e.g. mask wearing, hand hygiene, social distancing, vaccine uptake when available), and cost-effectiveness. Type: Interventional Start Date: Jul 2021 |
Study of Remdesivir in Participants Below 18 Years Old With COVID-19
Gilead Sciences
COVID-19
The goals of this clinical study are to learn more about the study drug, remdesivir, and
how safe it is in participants less than 18 years old with coronavirus disease 2019
(COVID-19). expand
The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants less than 18 years old with coronavirus disease 2019 (COVID-19). Type: Interventional Start Date: Jul 2020 |
COVID-19 and Cancer Consortium Registry
Vanderbilt-Ingram Cancer Center
COVID-19
Invasive Malignancy (Any Type)
In this study we will collect granular information on cancer patients infected with
COVID-19, as rapidly as possible. The mechanism for collection of this information is a
de-identified centralized registry housed at Vanderbilt University Medical Center, with
data donations from internal and external... expand
In this study we will collect granular information on cancer patients infected with COVID-19, as rapidly as possible. The mechanism for collection of this information is a de-identified centralized registry housed at Vanderbilt University Medical Center, with data donations from internal and external health care professionals. Type: Observational [Patient Registry] Start Date: Mar 2020 |
Safety Study of SLV213 for the Treatment of COVID-19.
National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
This Phase 1 double blind, placebo-controlled study will evaluate the safety,
tolerability, and pharmacokinetics (PK) of multiple ascending doses (MAD) of SLV213 in
healthy male and female participants, 18-65 years of age. This study will help to select
the most likely suitable dose (e.g., at Maximum... expand
This Phase 1 double blind, placebo-controlled study will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple ascending doses (MAD) of SLV213 in healthy male and female participants, 18-65 years of age. This study will help to select the most likely suitable dose (e.g., at Maximum Tolerated Dose [MTD]) for the treatment of patients with COVID-19 in a pivotal study. This phase 1 double blind, placebo-controlled study will consist of three sequential cohorts of 12 participants each (8 SLV213 and 4 placebo), at doses of 400 mg every 12 hours (Q12h), 600 mg Q12h, and 800 mg Q12h administered orally (PO) for 7 days. After each cohort, a Safety Review Committee (SRC) will evaluate the safety of the regimen before proceeding to dose the next cohort. Randomization will occur into the respective cohorts as above. Upon meeting the Inclusion/Exclusion criteria, subjects will begin treatment with SLV213 or placebo per their assigned cohort. The primary objective is to evaluate the safety and tolerability of multiple ascending doses of SLV213 for 7 days in healthy participants. Type: Interventional Start Date: Apr 2024 |
An Observational Study of Neurologic Function After COVID-19 Infection
National Institute of Neurological Disorders and Stroke (NINDS)
COVID-19
Background:
COVID-19 is an infection caused by a coronavirus. It can affect different parts of the
body. For most people, it causes fevers or trouble breathing. Some people can have
symptoms long after they recover. Researchers want to learn if there are signs of changes
in the nervous system that... expand
Background: COVID-19 is an infection caused by a coronavirus. It can affect different parts of the body. For most people, it causes fevers or trouble breathing. Some people can have symptoms long after they recover. Researchers want to learn if there are signs of changes in the nervous system that may be related to COVID-19. Objective: To test the nervous system (the brain and nerves) in people who have had COVID-19 yet still have certain symptoms even after recovering. Eligibility: People age 18 and older who had COVID-19 and still have neurologic symptoms after they recovered from the initial infection. Design: Participants will be screened with a medical record review. Participants will have a neurological exam. They will complete pen-and-paper tests of their memory and thinking. They will complete a smell test with 'scratch-and-sniff' booklets. They will give blood samples. Participants will have magnetic resonance imaging (MRI) of the brain. Soft padding or a coil will be placed around their head. They will lie on a table that slides in and out of the MRI scanner. They will get a contrast dye through an intravenous (IV) catheter. Participants blood pressure, blood flow, skin temperature, sweating, and breathing will be monitored. Participants will have an electrocardiogram to measure heart function. Participants will blow into a mouthpiece for several seconds. Participants will lie on a table that has a motor. The motor tilts the table. Participants will have blood drawn through an IV as the table tilts. Participants will have a lumbar puncture. A small needle will be inserted into the spinal canal to obtain fluid. Participants may repeat some tests 8 weeks to 1 year later. Type: Observational Start Date: Oct 2020 |
You and Me Healthy
Duke University
COVID-19
The You and Me Healthy Registry provides a resource for collecting information on people
currently living in the United States. The overall goal of the Registry is to create and
engage a community of people who may be eligible for participation in future research
studies aiming to answer research... expand
The You and Me Healthy Registry provides a resource for collecting information on people currently living in the United States. The overall goal of the Registry is to create and engage a community of people who may be eligible for participation in future research studies aiming to answer research questions about COVID-19 and other conditions. Type: Observational [Patient Registry] Start Date: Sep 2022 |
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19
Innovent Biologics (Suzhou) Co. Ltd.
COVID-19
This is a dose-finding, inferentially seamless Phase 1/2 study evaluating the safety,
tolerability and efficacy of IBI314 in Ambulatory Patients with COVID-19. expand
This is a dose-finding, inferentially seamless Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314 in Ambulatory Patients with COVID-19. Type: Interventional Start Date: Jan 2022 |
Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants...
GlaxoSmithKline
COVID-19
This Phase 2b study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and
safety of sotrovimab in pediatric participants from birth to less than (<)18 years old
with mild-to-moderate Coronavirus Disease-2019 (COVID-19) at high risk of disease
progression. expand
This Phase 2b study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of sotrovimab in pediatric participants from birth to less than (<)18 years old with mild-to-moderate Coronavirus Disease-2019 (COVID-19) at high risk of disease progression. Type: Interventional Start Date: Dec 2021 |
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger...
Merck Sharp & Dohme LLC
Papillomavirus Infections
Coronavirus Disease (COVID-19)
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen
of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of
a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and
mRNA-1273 vaccines in boys and girls... expand
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and girls 9 to 11 years of age. Type: Interventional Start Date: Mar 2022 |
Study Utilizing BIOZEK COVID-19 Antigen Rapid Test
Mach-E B.V.
Covid-19 Testing
This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19
Antigen Rapid Test (Saliva) and BIOZEK COVID-19 Antigen Rapid Test (Nasopharyngeal Swab)
on samples that are self-collected; and to perform analysis to compare results. In
addition, to obtain RT-PCR test results,... expand
This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test (Saliva) and BIOZEK COVID-19 Antigen Rapid Test (Nasopharyngeal Swab) on samples that are self-collected; and to perform analysis to compare results. In addition, to obtain RT-PCR test results, performed prior to enrollment, and compare all three results. Type: Interventional Start Date: May 2021 |
Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients
University of Vermont
Covid19
The adaptive immune response, consisting of antiviral T and B cells, is critical for
providing protection against viruses such as SARS-CoV-2, both during an active infection
and later following a subsequent exposure. They can both also potentially contribute to
pathogenesis if they are overstimulated.... expand
The adaptive immune response, consisting of antiviral T and B cells, is critical for providing protection against viruses such as SARS-CoV-2, both during an active infection and later following a subsequent exposure. They can both also potentially contribute to pathogenesis if they are overstimulated. Despite these advances in knowledge, there are still significant gaps in understanding of what constitutes a protective or immunopathologic immune response and its durability. Significant knowledge gaps also remain pertaining to the early recognition of COVID patients with increased risk of clinical deterioration who require continued hospitalization and the use of more intensive treatments designed to improve outcomes. Data from non-COVID patients with MI show that platelet surface expression of FcγRIIa, the low-affinity receptor for the Fc fragment of immunoglobulin (Ig) G, identifies patients at high and low risk of subsequent cardiovascular events. Platelet expression of FcγRIIa is increased by interferon γ20 that is significantly elevated in severe COVID-19 infections. The high prevalence of arterial thrombosis among COVID-19 patients and the central role of thrombosis in respiratory failure support the hypothesis that elevated platelet expression of FcγRIIa will identify COVID patients at increased risk of thrombotic complications and clinical deterioration. In addition to the potential role of platelet activation in thrombosis associated with COIVD-19, the endothelium may also play a significant role. The investigators hypothesize that elevated EMPs in plasma will identify patients at high risk of thrombosis and clinical deterioration. To begin to address the knowledge gaps above and obtain preliminary data for future large grant submission, the investigators propose a small, prospective, single-center cohort study that will enroll patients hospitalized for COVID-19 infection and exhibiting a range of disease severity. Biosamples will be obtained and used to study T and B cells, antibody repertoire, and durability of protective immunity, and also to quantify platelet expression of FcγRIIa and circulating EMPs, as described in the protocol. Type: Observational Start Date: Feb 2021 |
A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects
Vicore Pharma AB
COVID-19
This trial is a randomized, double-blind, placebo-controlled, parallel-group, 2-arm,
multicenter trial to evaluate the efficacy and safety of C21 versus placebo as add-on to
standard of care (SoC) in adult subjects with COVID-19.
The trial planned to enroll a total of maximum 300 randomized subjects,... expand
This trial is a randomized, double-blind, placebo-controlled, parallel-group, 2-arm, multicenter trial to evaluate the efficacy and safety of C21 versus placebo as add-on to standard of care (SoC) in adult subjects with COVID-19. The trial planned to enroll a total of maximum 300 randomized subjects, 150 per arm (oral C21 100 mg twice a day (BID) or placebo for 14 days) according to the 1:1 randomization. Type: Interventional Start Date: Sep 2021 |
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate...
BioNTech SE
SARS-CoV-2 Infection, COVID-19
This is a Phase 1/2/3 study in healthy children.
Dependent upon safety and/or immunogenicity data generated during the course of this
study, and the resulting assessment of benefit-risk, the safety, tolerability, and
immunogenicity of BNT162b2 in participants <6 months of age may subsequently be
evaluated. expand
This is a Phase 1/2/3 study in healthy children. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of BNT162b2 in participants <6 months of age may subsequently be evaluated. Type: Interventional Start Date: Mar 2021 |
Rapid Turnaround, Home-based Saliva Testing for COVID-19
Stanford University
Covid19
The aim of the study is to demonstrate the feasibility and validity of a saliva based
home surveillance monitoring test for SARS-CoV-2 infection.
Participants will be asked to carry out as many tests as are included in the bag they are
provided, on a daily basis until they are used up. expand
The aim of the study is to demonstrate the feasibility and validity of a saliva based home surveillance monitoring test for SARS-CoV-2 infection. Participants will be asked to carry out as many tests as are included in the bag they are provided, on a daily basis until they are used up. Type: Interventional Start Date: Nov 2020 |
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
Jennifer Woyach
Aplastic Anemia
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Monoclonal B-Cell Lymphocytosis
Monoclonal Gammopathy of Undetermined Significance
This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well
it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help
improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while
preserving overall immune function.... expand
This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing. Type: Interventional Start Date: Oct 2020 |
Community Care Intervention to Decrease COVID-19 Vaccination Inequities
RAND
COVID-19 Vaccination
The purpose of this study is to find out if a community health workers (CHW) intervention
conducted in Federally Qualified Health Centers (FQHCs) can increase the number of adults
with chronic illnesses who are up-to-date with their COVID-19 and influenza vaccines. expand
The purpose of this study is to find out if a community health workers (CHW) intervention conducted in Federally Qualified Health Centers (FQHCs) can increase the number of adults with chronic illnesses who are up-to-date with their COVID-19 and influenza vaccines. Type: Interventional Start Date: Sep 2023 |
- Previous
- Next